Patent · US Active

Combination of an anti-CD16A antibody with a cytokine

US11535672B2 · kind B2 · utility

0Cited by

1References

28Claims

0Family size

Assignee

AFFIMED GMBH · DE

Inventors

Joachim Koch · Heidelberg, DE
Martin Treder · Heidelberg, DE
Jens Pahl · Dossenheim, DE
Uwe Reusch · Maikammer, DE
Thorsten Ross · Edingen-Neckarhausen, DE
Erich Rajkovic · Schriesheim, DE
Adelheid Cerwenka · Heidelberg, DE

Key dates

Filing date	Jul 24, 2019
Grant date	Dec 27, 2022
Priority date	—
Expiry date	Dec 26, 2039

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07K2317/732
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The invention relates to an anti-CD16A antigen binding protein for use in NK cell-based immunotherapy, wherein the anti-CD16A antigen binding protein is to be administered intermittently and in combination with a cytokine. In certain embodiments the antigen binding protein is a tetravalent and bispecific CD30/CD16A tandem diabody.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.